Mayo Clinic | Strategic Alliance Partners

July 24, 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 21, 2023

An overview of the DESTINY-CRC02 study, which looked at trastuzumab deruxtecan in patients with HER2+ metastatic colorectal cancer.

July 21, 2023

Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.

July 19, 2023

In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.

July 19, 2023

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

July 19, 2023

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

July 17, 2023

Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.

July 17, 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

July 17, 2023

Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.

July 17, 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

July 14, 2023

Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.

July 12, 2023

In this fifth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, walk through the key lessons learned from the prospective, multicenter PATHINDER study (NCT04241796), which evaluated a multicancer early detection test developed by GRAIL.

July 12, 2023

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

July 12, 2023

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

July 10, 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 10, 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

July 10, 2023

An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.

July 05, 2023

In this fourth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss existing concerns regarding multicancer early detection tests.

July 05, 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

July 05, 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.